title: Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation.
abstract: There is no standard surgical protocol of bisphosphonate-related osteonecrosis of the jaws (BRONJ), because of the impossibility to visualize this feature intraoperatively. The aim of this study was to introduce how to provide preoperative labeling of the viable bone with minocycline bone fluorescence technique (MBFT) by using VELscope® and investigate histopathologically.
  
  
  BACKGROUND
  The American Association of Oral and Maxillofacial Surgeons (AAOMS) and the Japanese Society of Oral and Maxillofacial Surgeons (JSOMS) now recommend a more conservative treatment strategy. There is no standard surgical protocol of bisphosphonate-related osteonecrosis of the jaws (BRONJ) because of the impossibility to visualize this feature intraoperatively. The aim of this study was to introduce a mechanism providing preoperative labeling of a viable bone using minocycline bone fluorescence technique (MBFT) with VELscope® and to histopathologically investigate.
  
  
  METHODS
  This report describes a surgical technique used in six patients with BRONJ who underwent jawbone resection under minocycline bone fluorescence imaging using VELscope®. Subsequently, we investigated and compared the clinical findings using VELscope® and histopathological findings.
  
  
  RESULTS
  Histopathological examinations showed that the non-fluorescent moiety was consistent with the BRONJ lesions.
  
  
  CONCLUSIONS
  The surgical treatments that were exactly performed using MBFT with VELscope® offered successful management of BRONJ. This bone fluorescence helped to define the margins of resection, thus improving surgical therapy for extended osteonecrosis.
authors.affiliation: Department of Science of Physical Function, Division of Maxillofacial Surgery, Kyushu Dental University, Fukuoka, Japan, r11yoshiga@fa.kyu-dent.ac.jp.
authors.forename: D
authors.initials: D
authors.lastname: Yoshiga
authors.forename: M
authors.initials: M
authors.lastname: Sasaguri
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: S
authors.initials: S
authors.lastname: Kokuryou
authors.forename: M
authors.initials: M
authors.lastname: Habu
authors.forename: M
authors.initials: M
authors.lastname: Oda
authors.forename: M
authors.initials: M
authors.lastname: Kodama
authors.forename: H
authors.initials: H
authors.lastname: Tsurushima
authors.forename: O
authors.initials: O
authors.lastname: Sakaguchi
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: J
authors.initials: J
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Morimoto
authors.forename: I
authors.initials: I
authors.lastname: Yoshioka
authors.forename: K
authors.initials: K
authors.lastname: Tominaga
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007430:Intraoperative Care / Q000379:methods*; D008334:Mandible / Q000473:pathology; D063168:Mandibular Osteotomy / Q000379:methods; D008437:Maxilla / Q000473:pathology; D063166:Maxillary Osteotomy / Q000379:methods; D008875:Middle Aged; D008911:Minocycline; D061848:Optical Imaging / Q000295:instrumentation / Q000379:methods*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D008911:Minocycline